RLMD - RELMADA THERAPEUTICS, INC.
IEX Last Trade
0.3501
-0.011 -3.228%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:25:11 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$0.36
-0.01
-3.13%
Fundamental analysis
26%
Profitability
25%
Dept financing
10%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.41%
1 Month
-86.91%
3 Months
-89.31%
6 Months
-87.91%
1 Year
-88.19%
2 Year
-87.99%
Key data
Stock price
$0.35
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.37 - $7.22
52 WEEK CHANGE
-$91.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Sergio Traversa
Region: US
Website: relmada.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: relmada.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Relmada Therapeutics, Inc. focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Its lead product candidate is Esmethadone, a new chemical entity and N-methyl-D-aspartate receptor antagonist.
Recent news